Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NanoViricides, Inc. (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the healthy subjects part of the Phase 1a/1b Clinical Trial of NV-CoV-2.
COVID-19 remains a serious and deadly threat. The virus is responsible for over 200,000 deaths in the U.S. since January 2022. It continues to mutate and generate new variants at a rapid rate, putting millions of people around the globe at risk.
28.11.2023 - SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the Company ), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported today that the . Seite 1